Tag : CRS

  • INDUSTRY ESSENTIALS
    Unlocking the full potential of CAR T-cell therapy in R/R MM: A consensus from the IMWG Immunotherapy Committee

    Chimeric Antigen Receptor T-cell (CAR T-cell) therapy has emerged as a transformative treatment for relapsed or refractory multiple myeloma (R/R MM), which remains challenging despite advances in conventional therapies. Targeting B-cell maturation antigen (BCMA), consistently expressed on malignant

    doctor name

    Dr. Sivakumar Palaniappan

    Consultant Hematologist, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

    doctor name

    Lancet Oncol. 2024

    Lin Y, Qiu L, Usmani S, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O’Dwyer M, Schjesvold F, Sidana S, van de Donk NWCJ, Weisel K, Zweegman S, Raje N, Rodriguez Otero P, Anderson Jr LD, Kumar S, Martin T, International Myeloma Working Group. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8):e374-e387.